Skip to main content

Eduardo Fidel Tizzano

Institutions of which they are part

Head of group
Genetics Medicine
Vall Hebron Institut de Recerca

Eduardo Fidel Tizzano

Institutions of which they are part

Head of group
Genetics Medicine
Vall Hebron Institut de Recerca

Projects

ADQUISICIÓN DE UN MICROSCOPIO CONFOCAL ESPECTRAL DE RASTREO DE ALTA RESOLUCIÓN DESTINADO A LA PLATAFORMA DE MICROSCOPÍA DE LA UNIDAD DE ALTA TECNOLOGÍA (UAT)

IP: Inmaculada Fuentes Camps
Collaborators: Miquel Vila Bover, Anna Meseguer Navarro, José García Arumí, Joan Gavaldà Santapau, Miguel Segura Ginard, Maria Nieves Martell Pérez-Alcalde, Victor Franco Puntes, Anna Santamaria Margalef, Carmen Espejo Ruiz, María José Buzón Gómez, Javier Inserte Igual, Anna Rosell Novel, Eduardo Fidel Tizzano, Trond Aasen
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 502000
Reference: EQC2019-006247-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

Implementación de una base de datos genómicos del gen SMN2 en pacientes con AME para evaluar la eficacia terapéutica: Correlación genotipo-fenotipo

IP: Eduardo Fidel Tizzano
Collaborators: -
Funding agency: asociación GaliciAME
Funding: 20080.2
Reference: GALICIAME/BECA/2019/TIZZANO
Duration: 19/12/2019 - 18/09/2020

Aproximación genómica en atrofia muscular espinal (AME): estudio de casos especiales de pacientes con AME.5q y caracterización de pacientes con AME-no-5q.

IP: Eduardo Fidel Tizzano
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI18/00687
Duration: 01/01/2019 - 30/06/2023

Estudios funcionales de mutaciones del gen CFTR para establecer una terapia personalizada en pacientes con Fibrosis Quística

IP: Eduardo Fidel Tizzano
Collaborators: Paula Fernández Álvarez, SILVIA GARTNER TIZZANO
Funding agency: Fundación Invest. Médica Mutua Madrileña
Funding: 104213
Reference: MM/XIV/RECERCA/2017/TIZZANO
Duration: 10/10/2017 - 30/09/2021

Related news

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

The research has studied the structure and function of proteins related to this degenerative disease and their interaction with SMN2 messenger RNA (mRNA), which is key to the evolution of patients.

Related professionals

Inca Vilar Sastre

Inca Vilar Sastre

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Cristina Prat Vidal

Cristina Prat Vidal

Research assistant
Transfusional Medicine
Read more
Shilena Narci Rodriguez

Shilena Narci Rodriguez

Infectious Diseases
Read more
Marina Llanas Martinez

Marina Llanas Martinez

Predoctoral researcher
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.